Atrium Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNA research report →
About the company
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy.
- CEO
- Kathleen Gallagher
- IPO
- 2026
- Employees
- 511
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $233.49M
- P/E
- -5.11
- P/S
- 11.39
- P/B
- 1.00
- EV/EBITDA
- 0.49
- Div Yield
- 0.00%
- Gross Margin
- 99.26%
- Op Margin
- -318.70%
- Net Margin
- -315.71%
- ROE
- -29.67%
- ROIC
- -23.91%
- Revenue
- $18.62M · 0.00%
- Net Income
- $-76,684,000 · 0.00%
- EPS
- $-4.48 · 0.00%
- Op Income
- $-76,814,000
- FCF YoY
- 0.00%
- 52W High
- $16.77
- 52W Low
- $11.40
- 50D MA
- $12.88
- 200D MA
- $13.33
- Beta
- 0.19
- Avg Volume
- 297.61K
Get TickerSpark's AI analysis on RNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RNA coverage
Recent articles, reports, and earnings notes.
No research on RNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RNA report →